Viamet announced that the FDA has granted Orphan Drug designation to VT-1129, a selective oral antifungal agent, for the treatment of cryptococcal meningitis.

In preclinical studies, VT-1129 has been shown to be a potent and selective, orally available inhibitor of fungal CYP51. VT-1129 blocks the production of ergosterol, an essential component of the fungal cell membrane, which is critical to fungal proliferation and survival. Additionally, VT-1129 has demonstrated substantial potency against Cryptococcus species and high concentrations within the central nervous system in preclinical studies.

RELATED: Isavuconazole Under Review for Invasive Fungal Infections

The company plans on submitting an Investigational New Drug (IND) Application for VT-1129 to the FDA during the first half of 2015.

For more information visit Viamet.com.